In-vitro activity of BMY 28142, a new aminothiazolyl cephalosporin

John C H Steele, Barbara H. Edwards, John Peter Rissing

Research output: Contribution to journalArticle

15 Scopus citations

Abstract

The in-vitro activity of BMY 28142, a new α-methoxyimino aminothiazolyl cephalosporin, was determined by microdilution broth techniques. The agent demonstrated excellent activity against recent clinical Enterobacteriaceae isolates with a 90% minimum inhibitory concentration (MIC90) of 0·25 mg/l or less for all but one species tested. BMY 28142 inhibited all Pseudomonas aeruginosa strains tested (MIC90=8·0 mg/l) as well as most other non-fermentative bacteria studied. Methicillin-susceptible Staphylococcus aureus were susceptible to BMY 28142 with MIC90=4·0 mg/l, while methicillin-resistant strains were generally resistant (MIC range 8->32 mg/l).

Original languageEnglish (US)
Pages (from-to)463-468
Number of pages6
JournalJournal of Antimicrobial Chemotherapy
Volume16
Issue number4
DOIs
StatePublished - Oct 1 1985

ASJC Scopus subject areas

  • Pharmacology
  • Microbiology (medical)
  • Infectious Diseases
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'In-vitro activity of BMY 28142, a new aminothiazolyl cephalosporin'. Together they form a unique fingerprint.

  • Cite this